Landmark NHS-Galleri multi-cancer blood-test trial missed its primary goal, but found real gains in earlier-stage detection

Evidence stage: Later-Stage HumanRegulatory status: InvestigationalGuideline status: Not addressed

Important context

  • Not yet peer-reviewed: This record's primary source is a conference late-breaking-abstract publication (ASCO 2026 / JCO 44 LBA100), not yet independently confirmed as a full peer-reviewed manuscript as of the last_reviewed date above.

The NHS-Galleri trial, a large randomized controlled trial run by the UK’s National Health Service in partnership with GRAIL, enrolled roughly 142,000 asymptomatic adults aged 50-77 to test whether adding an annual Galleri multi-cancer early detection (MCED) blood test — which looks for cell-free DNA signals shared across more than 50 cancer types — to standard cancer screening could catch cancers earlier and reduce late-stage diagnoses (ClinicalTrials.gov NCT05611632; ISRCTN91431511). Full results, presented at the 2026 ASCO Annual Meeting and published in the Journal of Clinical Oncology (DOI 10.1200/JCO.2026.44.17_suppl.LBA100), reported that the trial’s PRIMARY endpoint — a statistically significant reduction in COMBINED stage III and IV cancer diagnoses — was NOT met. Reported secondary findings were more favorable: annual Galleri testing reduced stage IV diagnoses by 22% in the trial’s second screening round and 26% in its third round, increased the overall cancer detection rate roughly four-fold when added to standard screening, found more stage I and II cancers than all of the NHS’s existing single-cancer screening programs combined, and reduced cancer diagnosis via emergency-department presentation by 25%. Galleri is not currently FDA-approved for cancer screening in the United States; in the US it is offered as a laboratory-developed test.

What This Means

The NHS-Galleri trial's PRIMARY endpoint — a statistically significant reduction in COMBINED stage III and IV cancer diagnoses — was NOT met. Reported secondary findings were more favorable: stage IV diagnoses fell 22% in the trial's second screening round and 26% in its third, the test roughly quadrupled overall cancer detection when added to standard screening, and it found more stage I/II cancers than all of the NHS's existing single-cancer screening programs combined.

What This Doesn't Mean

A missed primary endpoint means this trial did NOT establish, at a statistically significant level, that adding this test to screening reduces combined late-stage (III/IV) cancer diagnoses — the favorable secondary findings above are real but are not the same as meeting the trial's own pre-specified success criterion, and should not be reported as if the trial "succeeded." Galleri is not FDA-approved for cancer screening in the United States (it is offered there as a laboratory-developed test); this record makes no claim about its regulatory status outside the UK NHS trial context.

Why It Matters

A missed primary endpoint in a large, well-designed randomized trial is real, important evidence in its own right — not a story to omit or downplay — and this project's mission is to report exactly this kind of honest, mixed result, not just positive headlines; readers researching multi-cancer blood tests deserve to know this specific trial did not meet its own success bar, alongside the real gains it did find.

Promise & Proof

Proof — strength of the evidence 4 / 5
  • Base score from evidence stage: Later-Stage Human.
Promise — potential significance if later evidence holds up 3 / 5
  • Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
  • The record includes substantive editorial reasoning about why this discovery matters.
  • A distinct follow-on/confirmatory study or trial is already cited as a secondary source — the field is already building on this finding.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Asymptomatic adults aged 50-77 in the United Kingdom, randomized to annual Galleri multi-cancer early detection (MCED) blood testing added to standard NHS cancer screening, or standard screening alone, followed for cancer diagnoses over multiple screening rounds. (Adults)

This is a single trial in a UK population aged 50-77; results may not generalize to other age groups, populations, or healthcare-access contexts. Multi-cancer early-detection tests remain an active, evolving research area — this record should be re-checked against any later full peer-reviewed publication of these results (this record cites the ASCO 2026 late-breaking-abstract publication in JCO) before republication.

Full evidence details
Study design
Randomized controlled trial
Sample size
142000

Funding & Conflicts

Trial run by the UK National Health Service in partnership with GRAIL, LLC, the commercial developer of the Galleri test — not independently confirmed against a primary corporate/NHS-disclosure document.

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-13

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-13

Primary evidence supporting this story

Additional context

Why Should I Trust This?

  • 1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
  • Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

  1. Status change — Status changed from "Legacy / Unverified" to "In editorial review".
  2. Status change — Status changed from "In editorial review" to "Verified".

Last reviewed

Related discoveries

Landmark NHS-Galleri multi-cancer blood-test trial missed its primary goal, but found real gains in earlier-stage detection

https://cancerdiscoveries.com/discoveries/landmark-nhs-galleri-multi-cancer-blood-test-trial-missed-its-primary-goal-but-found-real-gains-in-earlier-stage-detection/

Evidence stage: Later-Stage Human

What This Means

The NHS-Galleri trial's PRIMARY endpoint — a statistically significant reduction in COMBINED stage III and IV cancer diagnoses — was NOT met. Reported secondary findings were more favorable: stage IV diagnoses fell 22% in the trial's second screening round and 26% in its third, the test roughly quadrupled overall cancer detection when added to standard screening, and it found more stage I/II cancers than all of the NHS's existing single-cancer screening programs combined.

What This Doesn't Mean

A missed primary endpoint means this trial did NOT establish, at a statistically significant level, that adding this test to screening reduces combined late-stage (III/IV) cancer diagnoses — the favorable secondary findings above are real but are not the same as meeting the trial's own pre-specified success criterion, and should not be reported as if the trial "succeeded." Galleri is not FDA-approved for cancer screening in the United States (it is offered there as a laboratory-developed test); this record makes no claim about its regulatory status outside the UK NHS trial context.

Why It Matters

A missed primary endpoint in a large, well-designed randomized trial is real, important evidence in its own right — not a story to omit or downplay — and this project's mission is to report exactly this kind of honest, mixed result, not just positive headlines; readers researching multi-cancer blood tests deserve to know this specific trial did not meet its own success bar, alongside the real gains it did find.

Important Limitations

  • This record's primary source is a conference late-breaking-abstract publication (ASCO 2026 / JCO 44 LBA100), not yet independently confirmed as a full peer-reviewed manuscript as of the last_reviewed date above.

Primary sources

  • NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening (Journal of Clinical Oncology, 2026 ASCO Annual Meeting) — https://doi.org/10.1200/JCO.2026.44.17_suppl.LBA100 (DOI 10.1200/JCO.2026.44.17_suppl.LBA100)

Date verified: 2026-08-13

Correction status: No correction or retraction